Rapamycin‐ameliorated diabetic symptoms involved in increasing adiponectin expression in diabetic mice on a high‐fat diet. Issue 7 (30th June 2017)

• Record Type: Journal Article
• Authors: Gong, Fang‐Hua; Ye, Yan‐Na; Li, Jin‐Meng; Zhao, Hai‐Yang; Li, Xiao‐Kun
• Is Part Of: Kaohsiung journal of medical sciences. Volume 33:Issue 7(2017)
• Page Start: 321
• Page End: 326
• Publication Date: 2017-06-30
• Subjects: Rapamycin -- FGF21 -- Adiponectin -- Diabetic mice; Medicine -- Periodicals; 610.5
• DOI: 10.1016/j.kjms.2017.05.008
• Languages: English
• ISSNs: 1607-551X

Abstract

Abstract: Recent studies showed that rapamycin improved diabetic complications. Here, we investigated the metabolic effects of rapamycin in type 2 diabetes model (T2DM) mice. Mice were treated with a daily intraperitoneal injection of rapamycin at 2 mg/kg or vehicle only for 3 weeks and were maintained on a high‐fat diet. The treated diabetic mice exhibited decreased body weight, blood glucose levels, and fat mass. FGF21 expression was suppressed in C57B/L6 mice, but adiponectin expression increased both in FGF21 KO and C57B/L6 mice. These results suggest that rapamycin may alleviate FGF21 resistance in mice on a high‐fat diet. The reduction of adipose tissue mass of the diabetic mice may be due to the increased adiponectin.